These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31610537)

  • 61. Four-Factor Prothrombin Complex Concentrate for the Reversal of Direct Oral Anticoagulants.
    Zada I; Wang S; Akerman M; Hanna A
    J Intensive Care Med; 2021 Jan; 36(1):58-62. PubMed ID: 31746285
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Orenes-Piñero E; Romiti GF; Romanazzi I; Bai Y; Carmo J; Proietti M; Marín F; Lip GYH
    Am J Cardiol; 2018 Sep; 122(5):785-792. PubMed ID: 30049460
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism.
    Bott-Kitslaar DM; McBane RD; Casanegra AI; Houghton DE; Froehling DA; Vlazny DT; Ashrani AA; Hodge DO; Vargas ER; Bartlett MA; Saadiq RA; Daniels PR; Shields RC; Lenz CJ; Lang TR; Wysokinski WE
    Mayo Clin Proc; 2019 Jul; 94(7):1242-1252. PubMed ID: 30737059
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation.
    Aronow WS; Shamliyan TA
    Am J Ther; 2019; 26(6):e679-e703. PubMed ID: 30461433
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 67. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
    Fenger-Eriksen C; Münster AM; Grove EL
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):651-9. PubMed ID: 24716468
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [New clinical perspectives in the management of oral direct anticoagulant agents].
    Marco P; Zamorano JL; Chana F; Llau JV
    Med Clin (Barc); 2014 Feb; 142(4):171-8. PubMed ID: 23866969
    [No Abstract]   [Full Text] [Related]  

  • 69. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors.
    Deitelzweig S; Neuman WR; Lingohr-Smith M; Menges B; Lin J
    J Med Econ; 2017 Dec; 20(12):1217-1223. PubMed ID: 28760063
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Real-world utilization of andexanet alfa.
    Brown CS; Scott RA; Sridharan M; Rabinstein AA
    Am J Emerg Med; 2020 Apr; 38(4):810-814. PubMed ID: 31870672
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
    Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
    Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry.
    Di Biase L; Briceno DF; Trivedi C; Mohanty S; Gianni C; Burkhardt JD; Mohanty P; Bai R; Gunda S; Horton R; Bailey S; Sanchez JE; Al-Ahmad A; Hranitzky P; Gallinghouse GJ; Reddy YM; Zagrodzky J; Hongo R; Beheiry S; Lakkireddy D; Natale A
    Heart Rhythm; 2016 Jun; 13(6):1197-202. PubMed ID: 26994940
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Apixaban and rivaroxaban in patients with cerebral venous thrombosis.
    Covut F; Kewan T; Perez O; Flores M; Haddad A; Daw H
    Thromb Res; 2019 Jan; 173():77-78. PubMed ID: 30481600
    [No Abstract]   [Full Text] [Related]  

  • 75. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism.
    Kimpton M; Carrier M
    Expert Opin Drug Saf; 2019 Apr; 18(4):313-320. PubMed ID: 30925842
    [TBL] [Abstract][Full Text] [Related]  

  • 76. International Normalized Ratio Is Significantly Elevated With Rivaroxaban and Apixaban Drug Therapies: A Retrospective Study.
    Ofek F; Bar Chaim S; Kronenfeld N; Ziv-Baran T; Berkovitch M
    Clin Ther; 2017 May; 39(5):1003-1010. PubMed ID: 28476405
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.
    Beyer-Westendorf J; Lensing AW; Arya R; Bounameaux H; Cohen AT; Wells PS; Middeldorp S; Verhamme P; Hughes R; Kucher N; Pap AF; Trajanovic M; Prins MH; Prandoni P; Weitz JI
    Thromb Res; 2017 Jan; 149():29-37. PubMed ID: 27886530
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation.
    Yoshimura A; Iriki Y; Ichiki H; Oketani N; Okui H; Maenosono R; Namino F; Miyata M; Ohishi M
    J Cardiol; 2017 Jan; 69(1):228-235. PubMed ID: 27131792
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting.
    Ghadimi K; Levy JH; Welsby IJ
    Anesth Analg; 2016 May; 122(5):1287-300. PubMed ID: 26983050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.